MRX vs. CBOE, BXP, CIB, FHN, SF, OHI, EVR, AFG, GL, and LINE
Should you be buying Medicis Pharmaceutical stock or one of its competitors? The main competitors of Medicis Pharmaceutical include Cboe Global Markets (CBOE), BXP (BXP), BanColombia (CIB), First Horizon (FHN), Stifel Financial (SF), Omega Healthcare Investors (OHI), Evercore (EVR), American Financial Group (AFG), Globe Life (GL), and Lineage (LINE). These companies are all part of the "finance" sector.
Medicis Pharmaceutical vs. Its Competitors
Medicis Pharmaceutical (NYSE:MRX) and Cboe Global Markets (NASDAQ:CBOE) are both finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.
Medicis Pharmaceutical pays an annual dividend of $0.56 per share and has a dividend yield of 1.5%. Cboe Global Markets pays an annual dividend of $2.52 per share and has a dividend yield of 1.1%. Cboe Global Markets pays out 33.0% of its earnings in the form of a dividend. Cboe Global Markets has increased its dividend for 1 consecutive years.
In the previous week, Cboe Global Markets had 14 more articles in the media than Medicis Pharmaceutical. MarketBeat recorded 15 mentions for Cboe Global Markets and 1 mentions for Medicis Pharmaceutical. Cboe Global Markets' average media sentiment score of 1.49 beat Medicis Pharmaceutical's score of 0.00 indicating that Cboe Global Markets is being referred to more favorably in the news media.
Cboe Global Markets has a net margin of 18.64% compared to Medicis Pharmaceutical's net margin of 0.00%. Cboe Global Markets' return on equity of 22.02% beat Medicis Pharmaceutical's return on equity.
Cboe Global Markets has higher revenue and earnings than Medicis Pharmaceutical.
82.7% of Cboe Global Markets shares are owned by institutional investors. 3.8% of Medicis Pharmaceutical shares are owned by company insiders. Comparatively, 0.2% of Cboe Global Markets shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Medicis Pharmaceutical presently has a consensus price target of $44.00, indicating a potential upside of 14.14%. Cboe Global Markets has a consensus price target of $219.64, indicating a potential downside of 6.63%. Given Medicis Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Medicis Pharmaceutical is more favorable than Cboe Global Markets.
Summary
Cboe Global Markets beats Medicis Pharmaceutical on 10 of the 16 factors compared between the two stocks.
Get Medicis Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Medicis Pharmaceutical Competitors List
Related Companies and Tools
This page (NYSE:MRX) was last updated on 7/7/2025 by MarketBeat.com Staff